Rifaximin liquid preparation

A technology of rifaximin and excipients, applied in the field of rifaximin liquid preparation, can solve the problems of low systemic utilization rate and the like

Pending Publication Date: 2022-04-26
バウシュ ヘルス アイルランド リミテッド
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, rifaximin has traditionally been neglected for the treatment of systemic infections caused by invasive organism...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rifaximin liquid preparation
  • Rifaximin liquid preparation
  • Rifaximin liquid preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0078] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0079] When ranges are used herein to describe, for example, amounts of a particular compound or ingredient, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The use of the term "about" when referring to a number or numerical range means that the referenced number or numerical range is an approximation within experimental variability (or within statistical experimental error) and that therefore the number or value Ranges can vary. The term "comprising" (and related terms such as "containing" or "having" or "comprising") includes embodiments such as "consisting of" or "consisting essentially of" the described features An embodiment of any composition of matter, method, or process.

[0080] 1. Definition

[0081] "Rifaximin"...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided herein are pharmaceutical compositions that enhance the intestinal level of soluble rifaximin, formulations comprising the compositions, and their use in the treatment of one or more intestinal related disorders.

Description

[0001] related application [0002] This application claims priority to U.S. Provisional Application No. 62 / 904,790, filed September 24, 2019, and U.S. Provisional Application No. 63 / 044,447, filed June 26, 2020, the entire contents of each of which are incorporated by reference into this article. Background technique [0003] Rifaximin (eg, Xifaxan®) is an oral broad-spectrum antibiotic with antimicrobial activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. Rifaximin is currently indicated for the treatment of traveler's diarrhea (TD), for maintaining remission of hepatic encephalopathy (HE), and for the treatment of irritable bowel syndrome with diarrhea (IBS-D). Other uses of rifaximin include, for example, the treatment of Clostridium difficile (C. difficile) infection, infectious diarrhea, small intestinal bacterial overgrowth (SIBO), inflammatory diseases, inflammatory bowel disease (IBD) and diverticular disease. Because rifaximin is largel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/437A61K47/44A61K47/14A61K47/26A61K47/10A61K47/12A61K47/22A61K9/08A61K9/48A61P31/04A61P1/00A61P1/16A61P9/00A61P9/10A61P25/16A61P25/28A61P25/00A61P35/02
CPCA61K31/437A61K47/44A61K47/14A61K47/26A61K47/10A61K47/12A61K47/22A61K9/08A61K9/4858A61K9/4825A61K9/4808A61P31/04A61P1/00A61P1/16A61P9/00A61P9/10A61P25/16A61P25/28A61P25/00A61P35/02A61K9/4866A61K9/5031Y02A50/30
Inventor A·J·安杰尔K·R·帕瓦R·S·皮莱
Owner バウシュ ヘルス アイルランド リミテッド
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap